Merck Singulair Switch NDA Limits Indication to Allergies, Omits Asthma
This article was originally published in The Tan Sheet
Executive Summary
Merck will try to convince an FDA advisory committee May 2 to partially switch its blockbuster Rx drug Singulair to OTC for allergy relief in adults only. The firm will not seek to switch the Rx indications for asthma or allergy relief in children.
You may also be interested in...
CAGR For OTC Switch Forecast At 5%, But Without Statins, Asthma Treatments
OTC switch product sales are estimated to grow at a compounded annual growth rate of 5% by 2019, with opportunities likely emerging in bladder control for women and sleep aids, according to Kline Market Research. But asthma drugs and statins are not likely to debut OTC soon, notes analyst Laura Mahecha.
CAGR For OTC Switch Forecast At 5%, But Without Statins, Asthma Treatments
OTC switch product sales are estimated to grow at a compounded annual growth rate of 5% by 2019, with opportunities likely emerging in bladder control for women and sleep aids, according to Kline Market Research. But asthma drugs and statins are not likely to debut OTC soon, notes analyst Laura Mahecha.
J&J/McNeil Consent Decree Prequel Tops OTC Stories, Switch Leads Topics In 2014
“The Tan Sheet” readers also made top stories of FDA’s rejection of Bayer’s petition for aspirin as primary prevention of heart attack stroke; advisors recommending FDA consider additional label warnings for OTC NSAIDS; and FDA seeking to overhaul its OTC drug monograph process to be “more agile and responsive.”